This company has been acquired
APEN Stock Overview
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Apollo Endosurgery, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.00 |
52 Week High | US$10.30 |
52 Week Low | US$3.49 |
Beta | 2.32 |
11 Month Change | 0.50% |
3 Month Change | 1.11% |
1 Year Change | 67.79% |
33 Year Change | 360.83% |
5 Year Change | 70.94% |
Change since IPO | -17.76% |
Recent News & Updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Apr 03Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?
Nov 30Recent updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Apr 03Is Apollo Endosurgery (NASDAQ:APEN) Weighed On By Its Debt Load?
Nov 30Is Apollo Endosurgery (NASDAQ:APEN) Using Too Much Debt?
Aug 05Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings
Aug 04Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Mar 02Is Apollo Endosurgery, Inc. (NASDAQ:APEN) Trading At A 20% Discount?
Aug 04Apollo Endosurgery: New Management Bounce Makes Weight Loss Specialist A Buy
Jun 28Is Apollo Endosurgery (NASDAQ:APEN) A Risky Investment?
May 05Apollo Endosurgery EPS beats by $0.05, beats on revenue
May 04A Look At The Intrinsic Value Of Apollo Endosurgery, Inc. (NASDAQ:APEN)
Mar 24What Percentage Of Apollo Endosurgery, Inc. (NASDAQ:APEN) Shares Do Insiders Own?
Mar 03Trade Alert: Neil Gagnon At Apollo Endosurgery, Inc. (NASDAQ:APEN), Has Just Spent US$146k Buying 2.8% More Shares
Feb 10We Think Apollo Endosurgery (NASDAQ:APEN) Has A Fair Chunk Of Debt
Jan 31Assessing Apollo Endosurgery
Dec 27If You Had Bought Apollo Endosurgery's (NASDAQ:APEN) Shares Three Years Ago You Would Be Down 36%
Dec 27Is It Too Late To Consider Buying Apollo Endosurgery, Inc. (NASDAQ:APEN)?
Dec 01Apollo Endosurgery EPS beats by $0.10, beats on revenue
Nov 05Shareholder Returns
APEN | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0.8% | 1.1% | 1.5% |
1Y | 67.8% | 28.6% | 33.1% |
Return vs Industry: APEN exceeded the US Medical Equipment industry which returned -13.3% over the past year.
Return vs Market: APEN exceeded the US Market which returned -11.4% over the past year.
Price Volatility
APEN volatility | |
---|---|
APEN Average Weekly Movement | 0.5% |
Medical Equipment Industry Average Movement | 8.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: APEN has not had significant price volatility in the past 3 months.
Volatility Over Time: APEN's weekly volatility has decreased from 12% to 1% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 202 | Chas McKhann | www.apolloendo.com |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to suture and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, and delays gastric content emptying, which assists the patient in losing weight under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.
Apollo Endosurgery, Inc. Fundamentals Summary
APEN fundamental statistics | |
---|---|
Market cap | US$579.72m |
Earnings (TTM) | -US$39.84m |
Revenue (TTM) | US$76.86m |
7.5x
P/S Ratio-14.6x
P/E RatioIs APEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
APEN income statement (TTM) | |
---|---|
Revenue | US$76.86m |
Cost of Revenue | US$34.43m |
Gross Profit | US$42.43m |
Other Expenses | US$82.27m |
Earnings | -US$39.84m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.69 |
Gross Margin | 55.20% |
Net Profit Margin | -51.84% |
Debt/Equity Ratio | 164.7% |
How did APEN perform over the long term?
See historical performance and comparison